New immune drug trial challenges standard chemo for lung cancer

NCT ID NCT03088540

Summary

This large, completed Phase 3 trial tested whether a new immunotherapy drug (cemiplimab) works better than standard platinum-based chemotherapy as the first treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have high levels of a marker called PD-L1. The study directly compared how long patients lived (overall survival) and how long their cancer was kept from growing (progression-free survival) between the two treatment approaches. It involved over 700 patients globally who had not received prior systemic treatment for their advanced cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clincial Study Site

    Viña del Mar, Chile

  • Clinical Study Site

    Albury, New South Wales, Australia

  • Clinical Study Site

    Wollongong, New South Wales, Australia

  • Clinical Study Site

    Fitzroy, Australia

  • Clinical Study Site

    Minsk, Belarus

  • Clinical Study Site

    Mogilev, Belarus

  • Clinical Study Site

    Barretos, Brazil

  • Clinical Study Site

    Curitiba, Brazil

  • Clinical Study Site

    Joinville, Brazil

  • Clinical Study Site

    Lajeado, Brazil

  • Clinical Study Site

    Mogi das Cruzes, Brazil

  • Clinical Study Site

    Passo Fundo, Brazil

  • Clinical Study Site

    Pelotas, Brazil

  • Clinical Study Site

    Recife, Brazil

  • Clinical Study Site

    Rio de Janeiro, Brazil

  • Clinical Study Site

    Salvador, Brazil

  • Clinical Study Site

    Santa Cecília, Brazil

  • Clinical Study Site

    São José do Rio Preto, Brazil

  • Clinical Study Site

    Dobrich, Bulgaria

  • Clinical Study Site

    Gabrovo, Bulgaria

  • Clinical Study Site

    Recoleta, Chile

  • Clinical Study Site

    Santiago, Chile

  • Clinical Study Site

    Temuco, Chile

  • Clinical Study Site

    Lanshan, Shandong, China

  • Clinical Study Site

    Guangdong, China

  • Clinical Study Site

    Harbin, China

  • Clinical Study Site

    Linyi, China

  • Clinical Study Site

    Xuzhou, China

  • Clinical Study Site

    Zhejiang, China

  • Clinical Study Site

    Barranquilla, Colombia

  • Clinical Study Site

    Bogotá, Colombia

  • Clinical Study Site

    Floridablanca, Colombia

  • Clinical Study Site

    Nový Jičín, Czechia

  • Clinical Study Site

    Pelhřimov, Czechia

  • Clinical Study Site

    Prague, Czechia

  • Clinical Study Site

    Batumi, Georgia

  • Clinical Study Site

    Pátrai, Achaia, Greece

  • Clinical Study Site

    Cholargós, Attica, Greece

  • Clinical Study Site

    Larissa, Greece

  • Clinical Study Site

    Pylaia, Greece

  • Clinical Study Site

    Gyula, Bekes County, Hungary

  • Clinical Study Site

    Tatabánya, Komárom-Esztergom, Hungary

  • Clinical Study Site

    Farkasgyepű, Veszprém megye, Hungary

  • Clinical Study Site

    Budapest, Hungary

  • Clinical Study Site

    Debrecen, Hungary

  • Clinical Study Site

    Zalaegerszeg, Hungary

  • Clinical Study Site

    Amman, Jordan

  • Clinical Study Site

    Irbid, Jordan

  • Clinical Study Site

    Bsalîm, Lebanon

  • Clinical Study Site

    Mazraat ech Choûf, Lebanon

  • Clinical Study Site

    Sidon, Lebanon

  • Clinical Study Site

    Kampung Baharu Nilai, Malaysia

  • Clinical Study Site

    Kuching, Malaysia

  • Clinical Study Site

    Pulau Pinang, Malaysia

  • Clinical Study Site

    Tanjong Bungah, Malaysia

  • Clinical Study Site

    Coahuila, Mexico

  • Clinical Study Site

    Cuautitlán, Mexico

  • Clinical Study Site

    Jalisco, Mexico

  • Clinical Study Site

    León, Mexico

  • Clinical Study Site

    Oaxaca City, Mexico

  • Clinical Study Site

    San Luis Potosí City, Mexico

  • Clinical Study Site

    Bacolod City, Philippines

  • Clinical Study Site

    Batangas, Philippines

  • Clinical Study Site

    Cebu, Philippines

  • Clinical Study Site

    City of Taguig, Philippines

  • Clinical Study Site

    Davao City, Philippines

  • Clinical Study Site

    Dąbrowa Górnicza, Poland

  • Clinical Study Site

    Gdynia, Poland

  • Clinical Study Site

    Krakow, Poland

  • Clinical Study Site

    Lodz, Poland

  • Clinical Study Site

    Olsztyn, Poland

  • Clinical Study Site

    Poznan, Poland

  • Clinical Study Site

    Prabuty, Poland

  • Clinical Study Site

    Radom, Poland

  • Clinical Study Site

    Rzeszów, Poland

  • Clinical Study Site

    Torun, Poland

  • Clinical Study Site

    Warsaw, Poland

  • Clinical Study Site

    Wodzisław Śląski, Poland

  • Clinical Study Site

    Floreşti, Romania

  • Clinical Study Site

    Ploieşti, Romania

  • Clinical Study Site

    Timișoara, Romania

  • Clinical Study Site

    Ufa, Republic Bashkortost, Russia

  • Clinical Study Site

    Pushkin, Sankt-Peterburg, Russia

  • Clinical Study Site

    Arkhangelsk, Russia

  • Clinical Study Site

    Belgorod, Russia

  • Clinical Study Site

    Chelyabinsk, Russia

  • Clinical Study Site

    Kaluga, Russia

  • Clinical Study Site

    Kazan', Russia

  • Clinical Study Site

    Kemerovo, Russia

  • Clinical Study Site

    Kislino, Russia

  • Clinical Study Site

    Kursk, Russia

  • Clinical Study Site

    Omsk, Russia

  • Clinical Study Site

    Pyatigorsk, Russia

  • Clinical Study Site

    Samara, Russia

  • Clinical Study Site

    Saransk, Russia

  • Clinical Study Site

    Sochi, Russia

  • Clinical Study Site

    Yekaterinburg, Russia

  • Clinical Study Site

    Manresa, Barcelona, Spain

  • Clinical Study Site

    Barcelona, Spain

  • Clinical Study Site

    Pamplona, Spain

  • Clinical Study Site

    Chang-hua, Taiwan

  • Clinical Study Site

    Hualien City, Taiwan

  • Clinical Study Site

    Hat Yai, Changwat Songkhla, Thailand

  • Clinical Study Site

    Lopburi, Muang, Thailand

  • Clinical Study Site

    Chiang Rai, Thailand

  • Clinical Study Site

    Khon Kaen, Thailand

  • Clinical Study Site

    Lampang, Thailand

  • Clinical Study Site

    Phitsanulok, Thailand

  • Clinical Study Site

    Ratchathewi, Thailand

  • Clinical Study Site

    Udon Thani, Thailand

  • Clinical Study Site

    Edirne, Turkey (Türkiye)

  • Clinical Study Site

    Samsun, Turkey (Türkiye)

  • Clinical Study Site

    Dnipro, Ukraine

  • Clinical Study Site

    Ivano-Frankivsk, Ukraine

  • Clinical Study Site

    Kharkiv, Ukraine

  • Clinical Study Site

    Kherson, Ukraine

  • Clinical Study Site

    Kirovohrad, Ukraine

  • Clinical Study Site

    Uzhhorod, Ukraine

  • Clinical Study Site

    Vinnytsia, Ukraine

  • Clinical Study Site

    Zaporizhzhya, Ukraine

  • Clinical Study Site #1

    Kuala Lumpur, Malaysia

  • Clinical Study Site #1

    Quezon City, Philippines

  • Clinical Study Site #1

    Bangkok, Thailand

  • Clinical Study Site #2

    Kuala Lumpur, Malaysia

  • Clinical Study Site #2

    Quezon City, Philippines

  • Clinical Study Site #2

    Bangkok, Thailand

  • Clinical Study Site #3

    São Paulo, Brazil

  • Clinical Study Site #4

    São Paulo, Brazil

  • Clinical Study Site #6

    Tbilisi, Georgia

  • Clinical Study Site 1

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinical Study Site 1

    São Paulo, Brazil

  • Clinical Study Site 1

    Shanghai, China

  • Clinical Study Site 1

    Tianjin, China

  • Clinical Study Site 1

    Tbilisi, Georgia

  • Clinical Study Site 1

    Athens, Greece

  • Clinical Study Site 1

    Thessaloniki, Greece

  • Clinical Study Site 1

    Monterrey, Mexico

  • Clinical Study Site 1

    Manila, Philippines

  • Clinical Study Site 1

    Craiova, Romania

  • Clinical Study Site 1

    Moscow, Russia

  • Clinical Study Site 1

    Saint Petersburg, Russia

  • Clinical Study Site 1

    Tomsk, Russia

  • Clinical Study Site 1

    Kaohsiung City, Taiwan

  • Clinical Study Site 1

    New Taipei City, Taiwan

  • Clinical Study Site 1

    Taichung, Taiwan

  • Clinical Study Site 1

    Taipei, Taiwan

  • Clinical Study Site 1

    Adana, Turkey (Türkiye)

  • Clinical Study Site 1

    Ankara, Turkey (Türkiye)

  • Clinical Study Site 1

    Istanbul, Turkey (Türkiye)

  • Clinical Study Site 1

    Izmir, Turkey (Türkiye)

  • Clinical Study Site 1

    Kiev, Ukraine

  • Clinical Study Site 1

    Kyiv, Ukraine

  • Clinical Study Site 2

    Porto Alegre, Brazil

  • Clinical Study Site 2

    São Paulo, Brazil

  • Clinical Study Site 2

    Shanghai, China

  • Clinical Study Site 2

    Tianjin, China

  • Clinical Study Site 2

    Tbilisi, Georgia

  • Clinical Study Site 2

    Athens, Greece

  • Clinical Study Site 2

    Thessaloniki, Greece

  • Clinical Study Site 2

    Monterrey, Mexico

  • Clinical Study Site 2

    Manila, Philippines

  • Clinical Study Site 2

    Craiova, Romania

  • Clinical Study Site 2

    Moscow, Russia

  • Clinical Study Site 2

    Saint Petersburg, Russia

  • Clinical Study Site 2

    Tomsk, Russia

  • Clinical Study Site 2

    Kaohsiung City, Taiwan

  • Clinical Study Site 2

    New Taipei City, Taiwan

  • Clinical Study Site 2

    Taichung, Taiwan

  • Clinical Study Site 2

    Taipei, Taiwan

  • Clinical Study Site 2

    Adana, Turkey (Türkiye)

  • Clinical Study Site 2

    Ankara, Turkey (Türkiye)

  • Clinical Study Site 2

    Istanbul, Turkey (Türkiye)

  • Clinical Study Site 2

    Izmir, Turkey (Türkiye)

  • Clinical Study Site 2

    Kiev, Ukraine

  • Clinical Study Site 2

    Kyiv, Ukraine

  • Clinical Study Site 3

    Porto Alegre, Brazil

  • Clinical Study Site 3

    Tbilisi, Georgia

  • Clinical Study Site 3

    Athens, Greece

  • Clinical Study Site 3

    Thessaloniki, Greece

  • Clinical Study Site 3

    Monterrey, Mexico

  • Clinical Study Site 3

    Moscow, Russia

  • Clinical Study Site 3

    Saint Petersburg, Russia

  • Clinical Study Site 3

    Taipei, Taiwan

  • Clinical Study Site 3

    Ankara, Turkey (Türkiye)

  • Clinical Study Site 3

    Istanbul, Turkey (Türkiye)

  • Clinical Study Site 3

    Izmir, Turkey (Türkiye)

  • Clinical Study Site 4

    Tbilisi, Georgia

  • Clinical Study Site 4

    Saint Petersburg, Russia

  • Clinical Study Site 4

    Ankara, Turkey (Türkiye)

  • Clinical Study Site 4

    Istanbul, Turkey (Türkiye)

  • Clinical Study Site 5

    Tbilisi, Georgia

  • Clinical Study Site 5

    Ankara, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.